Steven Knapper MRCP, FRCPath, DM

Steve Knapper is an academic clinical haematologist, combining the role of Clinical Reader in the Institute of Cancer and Genetics at Cardiff University with clinical work as an Honorary Consultant Haematologist at the University Hospital of Wales where he currently acts as a haematological cancer lead clinician.

His clinical practice is predominantly in myeloid haematological cancers, particularly acute myeloid leukaemia, myeloproliferative neoplasms and myelodysplastic syndromes. My chief research interest lies in the development of targeted therapeutic agents in myeloid malignancies; this includes pre-clinical laboratory studies on FLT3 inhibition, TAM kinase inhibition and reactive oxygen species manipulation and clinical research including 'back to bench' laboratory projects running alongside clinical trials.

He is extensively involved in the development of clinical research at a national level through membership in the UK NCRI AML and Myeloproliferative Neoplasms Clinical Study Groups. He co-lead early-phase clinical trials within the Welsh Cancer Research Centre. He is the chief investigator of MONOCLE - a UK study of belinostat in chronic myelomonocytic leukaemia, and co-chief investigator of the AML18 trial. His other roles include Cardiff lead for the Bloodwise Trials Acceleration Programme and the lead of Cardiff University School of Medicine medical undergraduate haematology teaching.